Main content

Alert message

efrat dagan 2

Research Interests:

  • Hereditary breast-ovarian cancer
  • Cancer genetics
  • Human genetics
  • Genetic susceptibility to late onset diseases
  • Genetic counseling


Academic Rank: Associate Professor

This email address is being protected from spambots. You need JavaScript enabled to view it.


1984-1988  Hebrew University of Jerusalem  School of Nursing; B.N., R.N.

1989-1993  Technion - Israel Institute of Technology, Haifa Faculty of Medical Sciences; M.A. in Pharmacology

1995-2000  Technion - Israel Institute of Technology, Haifa Faculty of Medical Sciences; Ph.D. in Human Genetics



Articles in Refereed Journals:

  • Weizman R, Dagan E, Snyder HS, Gavish M (1997). Impact of pregnancy and lactation on GABA-A receptor and central-type and peripheral-type benzodiazepine receptors. Brain Research. 752:307-14.
  • Dagan E, Gershoni-Baruch R (1997). BRCA1 and BRCA2 susceptibility genes for breast and ovarian cancer. Harefuah. 133:455-7 (in Hebrew).
  • Gershoni-Baruch R, Dagan E, Kepten I, Freid J (1997). Co-segregation of BRCA1 185delAG mutation and BRCA2 6174delT in one single family. European Journal of Cancer. 33: 2283-4.
  • Friedman E, Bruchim Bar-Sade R, Kruglikova A, Risel S, Levy-Lahad E, Halle D, Bar-On E, Gershoni-Baruch R, Dagan E, Kepten I, Peretz T, Lerer I, Wienberger N, Shushan A, Abelliovich AD – The Israeli Breast Cancer Consortium (1998). Double and compound heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes. American Journal of Human Genetics. 63:1224-7.
  • Weizman R, Dagan E, Kaplan B, Karp L, Malmud S, Snyder SH, Gavish M (1999). Platelet peripheral-type benzodiazepine receptors in pregnancy and lactation. Neuropsychopharmacology. 21: 513-8.
  • Gershoni-Baruch R, Dagan E, Freid J, Kepten I, Robinson E (1999). BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer. European Journal of Human Genetics. 7: 833-6.
  • Gershoni-Baruch R, Dagan E, Bruchim Bar-Sade R, Fried G, Sverdlov-Shiri R, Zelickson G, Friedman E (‏2000). Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared to familial early breast cancer. European Journal of Cancer. 36: 983-6.
  • Gershoni-Baruch R, Patael Y, Dagan E, Figer A, Kasinetz L, Kaduri E, Bruchim Bar-Sade R, Friedman E (2000). Association of the I1307K APC mutation with hereditary and sporadic breast/ovarian cancer: more questions than answers. British Journal of Cancer. 83(2):153-5.
  • Gershoni-Baruch R, Dagan E, Israeli D, Kasinetz L, Kaduri E, Friedman E (2000). Association of the C677T polymorphism in the MTHFR gene and/or ovarian cancer risk in Jewish women. European Journal of Cancer. 36:2313-6.
  • Sverdlov-Shiri R, Oefner P, Green L, Baruch RG, Wagner T, Kruglikova A, Haitchick S, Hofstra RM, Papa MZ, Mulder I, Rizel S, Bar Sade RB, Dagan E, Abdeen Z, Goldman B, Friedman E (2000). Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer. Human Mutation. 16:491-501.
  • Sverdlov-Shiri R, Bruchim Bar-Sade R, Gershoni-Baruch R, Barshack I, Hirsh-Yehezkel G, Dagan E, Feimesser M, Figer A, Friedman E (2000). Genetic analyses of male breast cancer in Israel. Genetic Testing. 4:313-7.
  • Levi-Lahad E, Lahad A, Eisenberg S, Dagan E, Paperna T, Kasinetz L, Catane R, Kaufman B, Renbaum P, Gershoni-Baruch R (2001). A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proceeding National Academy of Science. 98:3232-6.
  • Dagan E and Gershoni-Baruch R (2001). Hereditary breast/ovarian cancer: Pitfalls in genetic counseling. Clinical Genetics. 60:310-3.
  • Dagan E and Gershoni-Baruch R (2002b). Anticipation in hereditary breast cancer. Clinical Genetics. 62:147-50.
  • Drach-Zahavy A, Dagan E (2002). From caring to managing and beyond: An examination of the head nurse’s role. Journal of Advanced Nursing. 38(1):19-28.
  • Dagan E, Friedman E, Carmi N, Gershoni-Baruch R (2002). Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: Association with breast/ovarian cancer phenotype. European Journal of Human Genetics. 10:724-8.
  • Gal I, Gershoni-Baruch R, Haber D, Dagan E, Eisenberg-Barzilai S, Zidan J, Friedman E (2004). The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: Occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers. Familial Cancer. 3:11-4.
  • Dagan E and Gil S (2004). Being a BRCA1/2 mutation carrier: Women’s psychological distress and ways of coping. Journal of Psychosocial Oncology 22:93-106.
  • Quintana-Murci LGal IBakhan TQuach HSayar SHShiri-Sverdlov RBaruch RGMcElreavey KDagan ENarod SFriedman E (2005). The Tyr978X BRCA1 mutation: Occurrence in non-Jewish Iranians and haplotype in French-Canadian and non-Ashkenazi Jews. Familial Cancer. 4:85-8.
  • Karban A, Dagan E, Eliakim R, Herman A, Nesher S, Berkovitz D, Shamir R, Gershoni-Baruch (2005). Prevalence and significance of the familial Mediterranean fever gene in patients with Crohn’s disease. Genes and Immunity. 6:134-39.
  • Karban A, Dagan E, Eliakim R, Herman A, Nesher S, Berkovitz D, Shamir R, Gershoni-Baruch (2005). Prevalence and significance of the familial Mediterranean fever gene in patients with Crohn’s disease. Genes and Immunity. 6:134-39.
  • Simchoni SFriedman EKaufman BGershoni-Baruch ROrr-Urtreger AKedar-Barnes IShiri-Sverdlov RDagan ETsabari SShohat MCatane RKing MCLahad ALevy-Lahad E (2006). Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. Proceeding National Academy of Science U S A. 7;103(10):3770-4.
  • Gal IKimmel GGershoni-Baruch RPapa MZDagan E, Shamir RFriedman E (2006). A specific RAD51 haplotype increases breast cancer risk in Jewish non-Ashkenazi high-risk women. European Journal of Cancer. 42(8):1129-34.
  • Dagan EBrik RBroza YGershoni-Baruch R (2006). Henoch-Schonlein purpura: Polymorphisms in thrombophilia genes. Pediatric Nephrology 21(8):1117-21.
  • Dagan E, Laitman Y, Levanon N, Feuer A, Sidi AA, Baniel J, Korach Y, Ben Baruch G, Friedman E, Gershoni Baruch R (2006). The 471delAAAG mutation and C353T polymorphism in the RNASEL gene in sporadic and inherited cancer in Israel. Familial Cancer. 5(4):389-95.
  • Dagan E, Gil S, Gershoni-Baruch R (2008). Socio-demographic and clinical profile of BRCA1/2 mutation carriers opting for prophylactic oophorectomy. Preventive Medicine. 46(5):470-2.
  • Dagan E (2008). Predominant Ashkenazi BRCA1/2 mutations in families with pancreatic cancer. Genetic Testing. 12(2):267-71.
  • Dagan E and Shochat T (2009). Quality of life in asymptomatic BRCA1/2 mutation carriers. Preventive Medicine. 48(2):193-6.
  • Bezalel Y, Gershoni-Baruch R, Dagan E, Lidar M, Livneh A (2009 suppl. 53). The 3435T polymorphism in the ABCB1 gene and colchicine unresponsiveness in familial Mediterranean fever. Clinical and Experimental Rheumatology. 27:s103.
  • Dagan E and Goldblatt H (2009). The twilight zone between health and sickness: A qualitative exploration with asymptomatic BRCA1/2 mutation carriers. Women & Health. 49:263-279.
  • Shochat T and Dagan E (2010). Sleep disturbances in asymptomatic BRCA1/2 mutation carriers: Women at high risk for breast-ovarian cancer. Journal of Sleep Research. 19:333-340.
  • Dagan E, Gershoni-Baruch R, Ihab K, ##Mory A, Amar N, Brik R (2010). MEFV, TNF1rA, CARD15 and NLRP3 mutation analysis in PFAPA. Rheumatology International. 30:633-6.
  • Laitman Y, Borsthein RT, Stoppa-Lyonnet D, Dagan E, Castera L, Goislard M, Gershoni-Baruch R, Goldberg H, Kaufman B, Ben-Baruch N, Zidan J, Maray T, Soussan-Gutman L, Friedman E (2011) Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel. Breast Cancer Research and Treatment. 127(2):489-95.
  • Baruch Y, Dagan E, Rozenbaum M, Massimo F, Gershoni-Baruch R, Rosner I (2011). MEFV, TNFRSF1A and CARD15 mutation analysis in Behcet's Disease. Clinical and Experimental Rheumatology. 29(4 Suppl 67):S24-7.
  • Dagan E, Baruch Y, Massimo F , Rozenbaum M, Rosner I, Gershoni-Baruch R. (2012) Vascular Behcet and Mutations in Thrombogenic Genes: MTHFR, Factor V and Prothrombin. Genetic Testing and Molecular Biomarkers. 16(1):30-5.
  • Inzelberg R, Cohen OS, Aharon-Peretz J, Schlesinger I, Gershoni-Baruch R, Djaldetti R, Nitsan Z, Ephraty L, Tunkel O, Kozlova E, Inzelberg L, Kaplan N, Fixler Mehr T, Mory A, Dagan E, Schechtman E, Friedman E, Hassin-Baer S. (2012). The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers. Neurology. 13;78(11):781-6.
  • Mory A, Dagan E, Illi B, Duquesnoy P, Mordechai S, Shahor I, Romani S, Hawash-Moustafa N, Mandel H, Valente EM, Amselem S, Gershoni-Baruch R. (2012). A nonsense mutation in the human homolog of Drosophila rogdi causes Kohlschutter–Tonz Syndrome. American Journal of Human Genetics. 90:708-14.
  • Shiloh S, Dagan E, Friedman I, Blank N, Friedman E. (2013). A follow-up study on men tested for BRCA1/BRCA2 mutations: impacts and coping processes. Psycho-oncology. 22(2):417-25.
  • Livnat G, Bar-Yoseph R, Mory A, Dagan E, Elias N, Gershoni R, Bentur L. (2014). Duplication in CHIT1 gene and the risk for Aspergillus lung disease in CF patients. Pediatric Pulmonology. 49(1):21-7.
  • Mory A, Ruiz X F., Dagan E, Evgenia A, Kurolap A, Parés X, Farrés J and Gershoni-Baruch R. (2014). A missense mutation in the ALDH1A3 gene causes isolated anophthalmia/microphthalmia in nine individuals from a large consanguineous kindred. European Journal of Human Genetics. 22(3):419-22.
  • Dagan E, Cohen Y, ##Mory A, Adir V, Borochowitz Z, Raanani H, Kurolap A, Melikhan-Revzin S, Meirow D, Gershoni-Baruch R. (2014). BRCA1/2 mutations and FMR1 alleles are randomly distributed: a case control study. European Journal of Human Genetics. 22(3):277-9.
  • Mory A, Dagan E, Shahor I, Mandel H, Illi B, Zolotushko J, Kurolap A, Chechik E,   Valente EM, Amselem S, and Gershoni-Baruch R. (2014). Kohlschutter-Tonz Syndrome: Clinical and Genetic Insights gained from sixteen cases deriving from a close knit village in Northern Israel. Pediatric Neurology. 50(4):421-6.
  • Dagan E, Gershoni-Baruch R, Goldberg Y, Fried G. (2014). “I do not want my baby to suffer as I did” Prenatal and preimplantation genetic diagnosis for BRCA1/2 mutations: A case report and genetic counseling considerations. Genetic Testing and Molecular Biomarkers. 18(7):461-6.
  • Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, Aderka D, Paluch-Shimon S, Kaufman B, Gershoni-Baruch R, Hedley D, Moore MJ, Friedman E, Gallinger S. (2014). Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. British Journal of Cancer. 111(6):1132-8.
  • Melikhan-Revzin S, Kurolap A, Dagan E, Mory A, Gershoni-Baruch R. (2015). Hereditary Lymphedema. Lymphatic Research & Biology. 13(2):107-11.
  • Dagan E, Schlesinger I, Ayoub M, Mory A, Peretz-Aharon J, Gershoni-Baruch R. (2015). The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in ‎Ashkenazi Jews. Parkinsonism & Related Disorders. ‎21(9):1067-71.
  • Dagan E, Adir V, Schlesinger I, Borochowitz Z, #Ayoub M, Mory A, Peretz-Aharon J, Gershoni-Baruch R. (2015). SMPD1 mutations and Parkinson disease. Parkinsonism & Related Disorders. 21(10):1296-7. Response to comment. doi: 10.1016/j.parkreldis.2015.08.019.
  • Dubovi I, Sharona T. Levy, Dagan E. (2015). The contribution of computerized simulation to medication calculation learning. Guf Yeda. 13:4-12. [In Hebrew].

Chapters in Scientific Books:

  • Dagan E and Gershoni-Baruch R (2010). Genetic disorders among Jews from Arab countries. In AS Teebi (Ed.), Genetic disorders among Arab population (2nd ed.)  (pp. 677-705). New-York, NY: Springer-Verlag. DOI 10.1007/978-3-642-05080-0_23.
  • Dagan E and Gershoni-Baruch R (2012). The Genetics of Pancreatic Cancer. In SK Srivastava (Ed.), Pancreatic cancer – clinical management (1st ed.) (pp. 1-14). Croatia, InTech.